This agreement was seen as a game-changer for a continent frustrated by the slowness of Western subsidies. But while only one-fifth of adults in Africa are fully vaccinated, according to the African Centers for Disease Control and Prevention, the order for vaccines has not arrived. Materialized.
Aspen has obtained orders for its Aspenovax vaccine and has obtained orders from Johnson
JOHNSON
j
“The challenge here is that we don’t know if we’re going to get more orders from J.
Without new orders, Aspen would have its full annual production capacity of 450 million doses, he said.
Aspen may receive directions from J
Most of the company’s COVID-19 production lines were intended to produce Aspenovax for Africa. Its initial plans were to increase annual capacity to 700 million doses through February and an additional expansion to one billion doses to meet expected demand.
However, its current production of Aspenovax is inactive lately. Without Orders from Aspenovax, Aspen would be forced to convert production to make anesthetics, Nicolaou said.
“So Africa is wasting its COVID vaccine capacity, the only one that exists on the continent,” he said. “Of course we cannot continue indefinitely with the vacant ranks. And we deserve to have an order soon. “